Abiopharma

News list

Gossamer Bio Inc (GOSS)

Event
May 10, 2022, 20:04 UTC

(99% Neutral tone) Gossamer Bio Inc (GOSS) Reports Q2 2022 Financial Results

Full text

News bot Sept. 24, 2025, 7:28 p.m.

📋 Gossamer Bio Inc (GOSS) - Financial Results

Filing Date: 2022-05-10

Accepted: 2022-05-10 16:04:37

Event Type: Financial Results

Event Details:

Gossamer Bio Inc (GOSS) Reports the reporting period Financial Results Gossamer Bio Inc (GOSS) announced its financial results for the period ending the reporting period. Key Financial Highlights:

Revenue: Not disclosed
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: 271623 No specific business highlights were provided.
- expected initiation of a Phase 1 clinical trial of GB7208
- expected initiation of the Phase 1b/2 STAR CNS study of GB5121
- expected in the fourth quarter of 2022

📊 Key Financial Metrics (Year-over-Year Comparison):

Metric	2022	2021	Change ($)	Change (%)
Operating Expenses Loss From Operations	-54.34K	-53.20K	$-1.14K	-2.14%
Other Income Expense Net Interest Income	224.00	193.00	$31.00	+16.06%
Other Income Expense Net Interest Expense	-3.47K	-4.78K	$1.31K	+27.47%
Other Income Expense Net Total Other Income Expense	-3.44K	-4.44K	$996.00	+22.44%
Other Income Expense Net Net Loss	-57.78K	-57.78K	$0.00	+0.00%
Other Income Expense Net Net Loss Per Share	-0.76	-0.76	$0.00	+0.00%
Balance Sheet Data Cash Equivalents Marketable Securities	271.62K	271.62K	$0.00	+0.00%
Loss from Operations	-54.34K	-53.20K	$-1.14K	-2.14%
Interest Income	224.00	193.00	$31.00	+16.06%
Interest Expense	-3.47K	-4.78K	$1.31K	+27.47%
Total Other Income/(Expense)	-3.44K	-4.44K	$996.00	+22.44%
Net Loss	-57.78K	-57.78K	$0.00	+0.00%
Cash and Marketable Securities	271.62K	271.62K	$0.00	+0.00%

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: Gossamer Bio Inc
Ticker Symbol: GOSS